Companies · Biotech / Pharma

Life Biosciences LLC

BOSTON · Biotech / Pharma · refined from filed group “Other

Diligence memoA one-page analyst read on Life Biosciences LLC — recommendation, valuation, rhythm, risks.
$123.4M
Total raised · real
2
Rounds
0.2×
Latest step-up
Top 6%
Sector rank · raised
Series C
Latest stage · inferred · Fri May 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Life Biosciences LLC has raised $123M over 2 rounds; too few niche peers to rank its valuation yet.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Dormant
  • Last raise 6.1 yr ago; this sector typically re-raises about every 15 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Life Biosciences LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
7.9 yr record
Peak capital year was 2020 with $93.0M across 2 filings.
Market position
ahead of 95% of Biotech / Pharma peers
Capital scale is ahead of 95% of Biotech / Pharma peers; modeled value is above 99% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2020: $93.0M across 2 filings.
  • Largest single filing was $74.8M on 2020-05-29.
  • Filing rows sum to $141.6M, while canonical raised total is $123.4M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Life Biosciences LLC is one of 227 Biotech / Pharma companies tracked from BOSTON. By capital raised it ranks among the largest (ahead of 95% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
10
Investors (latest)
2017
Year incorporated
2020-05-29
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries C · 2018-08-16 Raised $49M (real) Modeled valuation $1.8B (est)$49M$1.8BSeries C2018Series C · 2020-05-29 Raised $75M (real) Modeled valuation $2.8B (est)$75M$2.8BSeries C2020Series B · 2020-05-29 Raised $18M (real) Modeled valuation $669M (est)$18M$669MSeries B2020+$75M+$18MCumulative $142M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$48.6M · 2018
Series C extension$74.8M · 2020
Bridge · Series C-stage$18.2M · 2020smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$2.8B
Base estimate est.
$237.1M
Conservative case
$7.5B
Upside case
$498.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Series C · modeled $1.8B · 2018-08-162018Series C · modeled $2.8B · 2020-05-29Series B · modeled $668.8M · 2020-05-292020
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
48% low · 74% high
1.44×/yr
Annual markup
1.65×/yr upside case
6.0 yr
Elapsed time used
6.1 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
11 mo
Avg between rounds
$69.1M/yr
Capital velocity
7.9 yr
On record since
2018
First round
3
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 22× above median
This company$123.4M
Sector median$5.6M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.4× of median
This company$18.2M
Sector median$48.1M
Modeled value — vs sector median (estimate, all stages) 93× above median
This company$2.8B
Sector median$30.5M

Raised more than 95% of sector peers (real $). Modeled value above 99% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Imago BioSciences, Inc. · Series C Raised $137.5M · modeled $2.7B (est)BlueSphere Bio, Inc. · Series C Raised $55.6M · modeled $1.5B (est)Life Biosciences LLC (this company) Raised $123.4M · modeled $2.8B (est)Life Biosciences LLC
CompanyStageRaised · realValue · estvs peer med.
Life Biosciences LLC this companySeries C$123.4M$2.8B1.07×
Imago BioSciences, Inc.Series C$137.5M$2.7B1.00×
BlueSphere Bio, Inc.Series C$55.6M$1.5B0.55×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$48.6M2018-08-16$324.0M$1.8B90%
Series C$74.8M2020-05-29$498.5M$2.8B90%
Series B$18.2M2020-05-29$101.0M$668.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$48.6M2018-08-16
    • First recorded raise — entered as Series C.
    • 45 investors on this round.
  2. Series C$74.8M2020-05-29
    • Raised 21 mo later, in step with the ~15 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 506(c)).
    • 35 investors on this round.
  3. Series B$18.2M2020-05-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.1× smaller than the prior — bridge or down round.
    • 10 investors on this round.
Intelligence
2021 ~Q2
Modeled next raise · ~11mo cadence
$18.2M
Modeled next size est.range $18.2M$29.1M
0.2×
Last step-up
$69.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Alexander Tristan Edwards3 other2018-08
David Tristan Sinclair2 other2018-08
Brian Tristan Malone1 other2018-08
Adam Tristan Neumann2018-08
Amit Tristan Shashank2020-05
Bracken Tristan Darrell2018-08
Ilan Tristan Stern2020-05
Mehmood Tristan Khan2020-05
Stuart Tristan Gibson2018-08
Registry & provenance

Life Biosciences LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1751806
SEC CIK
2017
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Continuum Biosciences, Inc.Biotech / PharmaPre-Seed$500K$25.6Mnetwork2 shared operators · same sector
Manus Bio Inc.Biotech / PharmaSeries C$118.0M$108.4Msame sector · same stage
Elephas Biosciences CorpBiotech / PharmaSeries C$113.7M$560.6Msame sector · same stage
Sherlock Biosciences, Inc.Biotech / PharmaSeries C$112.8M$1.7Bsame sector · same stage
Imago BioSciences, Inc.Biotech / PharmaSeries C$137.5M$2.7Bsame sector · same stage
Coherus BioSciences, Inc.Biotech / PharmaSeries C$160.7M$258.3Msame sector · same stage
TwinStrand Biosciences, Inc.Biotech / PharmaSeries C$85.0M$132.4Msame sector · same stage
Pacific Biosciences Of California, Inc.Biotech / PharmaSeries C$190.3M$982.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
LifeVault Bio, Inc.Biotech / PharmaSeries B$595.3M91%
Genomic Life, Inc.Biotech / PharmaSeries A$55.9M86%
Outer Biosciences, LLCBiotech / PharmaSeed$66.1M86%
Animal Biosciences, Inc.Biotech / PharmaSeed$31.6M86%
Me Biosciences, Inc.Biotech / PharmaPre-Seed$25.6M86%
Scout Bio, Inc.Biotech / PharmaSeries B$104.3M85%
Split Biosciences, Inc.Biotech / PharmaSeed$23.0M85%
Continuum Biosciences, Inc.Biotech / PharmaPre-Seed$25.6M85%
Frequently asked
How much funding has Life Biosciences LLC raised?
Life Biosciences LLC has raised approximately $123.4M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Life Biosciences LLC's estimated valuation?
Provath's modeled valuation for Life Biosciences LLC is approximately $2.8B (modeled range $237.1M–$7.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Life Biosciences LLC at?
Life Biosciences LLC's latest modeled financing stage is Series C. Its most recent recorded round closed around Fri May 29.
What does Life Biosciences LLC do and where is it based?
Life Biosciences LLC operates in the Biotech / Pharma sector, based in BOSTON.
Explore related

See where Life Biosciences LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Life Biosciences LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.